MétaCan
Menu
Back to cohort

Adjunctive Perampanel for the Treatment of Drug-Resistant Primary Generalized Tonic-Clonic (PGTC) Seizures in Patients with Idiopathic Generalized Epilepsy (IGE): A Double-Blind, Randomized, Placebo-Controlled Phase III Trial (S31.007)

2015· article· en· W2165621508 on OpenAlexaboutno aff
Jacqueline A. French, Gregory L. Krauss, Robert Wechsler, Xuefeng Wang, Bree DiVentura, Christian Brandt, Eugen Trinka, Terence J. O’Brien, Antonio Laurenza, Anna Patten, Francesco Bibbiani

Bibliographic record

VenueNeurology · 2015
Typearticle
Languageen
FieldMedicine
TopicEpilepsy research and treatment
Canadian institutionsnot available
Fundersnot available
KeywordsPerampanelIdiopathic generalized epilepsyMedicinePlaceboEpilepsyDouble blindAntiepileptic drugAdjunctive treatmentRandomized controlled trialPediatricsAnesthesiaInternal medicinePsychiatryPathologyAlternative medicine

Abstract

fetched live from OpenAlex

OBJECTIVE: To assess the efficacy and safety of adjunctive perampanel for treating drug-resistant PGTC seizures in patients with IGE. BACKGROUND: The AMPA receptor antagonist perampanel is approved in 40 countries for the adjunctive treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 蠅12 years (蠅18 years in Canada). DESIGN/METHODS: Patients (蠅12 years; confirmed IGE; 蠅3 PGTC seizures in 8 weeks prior to randomization; 1-3 concomitant antiepileptic drugs) were recruited from 78 sites in 16 countries. This trial (NCT01393743) had Pre-randomization (4-week screening; 4-8 week Baseline), Randomization (4-week Titration, 13-week Maintenance, 4-week Follow-up), and Extension Phases. Patients were randomized (1:1) under double-blind conditions to placebo or perampanel 2 mg/day, uptitrated in weekly 2-mg increments to 8 mg/day or maximum-tolerated dose. Primary endpoints were percent change in PGTC seizure frequency per 28 days (Titration and Maintenance vs Baseline) and 50[percnt] responder rate (蠅50[percnt] reduction in PGTC seizure frequency during Maintenance vs Baseline). Adverse events (AEs) were recorded. RESULTS: Of 164 randomized patients, 162 comprised the full analysis set (perampanel, n=81; placebo, n=81). Median percent changes in PGTC seizure frequency (-76.5[percnt] vs -38.4[percnt]; P<0.0001), 50[percnt] responder rate (64.2[percnt] vs 39.5[percnt]; P=0.0019), and tonic-clonic seizure-free rate (30.9[percnt] vs 12.3[percnt]) all favored perampanel vs placebo. In the safety set (n=163), treatment-emergent AEs occurred in 82.7[percnt] of perampanel-treated patients (vs placebo, 72.0[percnt]). The AEs most frequently reported with perampanel vs placebo were dizziness (32.1[percnt] vs 6.1[percnt]), fatigue (14.8[percnt] vs 6.1[percnt]), and headache (12.3[percnt] vs 9.8[percnt]). Six perampanel-treated (7.4[percnt]) and seven placebo-treated (8.5[percnt]) patients experienced serious AEs, including two deaths (accidental drowning [perampanel] and sudden unexpected death in epilepsy [placebo]). CONCLUSIONS: Adjunctive perampanel improved control of drug-resistant PGTC seizures in patients aged 蠅12 years with IGE. Perampanel was well tolerated, with safety profile consistent with previous observations. Study Supported by: Eisai Inc

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.038
GPT teacher head0.315
Teacher spread0.277 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations13
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueNeurologySame topicEpilepsy research and treatmentFrench-language works237,207